进展期胃癌术后紫杉醇联合优福定化疗及同步放疗的临床观察  

Paclitaxel Combined with Tegafur-Uracil Chemotherapy and Concurrent Radiotherapy for Advanced Gastric Carcinoma Postoperation

作　　者：金明根 吴克华 陈智文 姜盛春 

机构地区：[1]上饶市肿瘤医院,江西上饶334000

出　　处：《肿瘤学杂志》2008年第11期920-922,共3页Journal of Chinese Oncology

摘　　要：[目的]评价进展期胃癌根治术后予以紫杉醇联合优福定化疗及同步放疗的疗效及治疗耐受性。[方法]71例进展期胃癌根治术后患者随机分为2个组,同步放化疗组(研究组)37例,采用TAX+UFT方案放疗,并同步放疗;单纯化疗组(对照组)34例,采用TLF化疗方案。比较两组的治疗毒副反应发生率及1年、3年生存率。[结果]研究组毒副反应发生率(81.1%)高于对照组(67.6%)(P=0.1936)。研究组1年、3年生存率分别为86.5%(32/37)、67.6%(25/37);对照组分别为64.7%(22/34)、41.2%(14/34)。两组1年、3年生存率比较均有显著性差异(P=0.0317,P=0.0256)。[结论]进展期胃癌根治术后采用紫杉醇联合优福定化疗及同步放疗,与术后单纯化疗相比能显著提高患者的1年、3年生存率;毒副反应能为患者所耐受。[Purpose] To evaluate the clinical efficacy and safety of combined concurrent chemotherapy （paclitaxel＋tegafur-uracil） and radiotherapy for advanced gastric carcinoma postoperation. [ Methods] Seventy-one cases with advanced gastric carcinoma after radical gastrectomy were randomly divided into two groups： 37 cases with TAX＋UFT regimen chemotherapy and radio-therapy（CR group） and 34 cases as control with TLF regimen chemotherapy alone（control group）. The toxicity, 1-and 3-year survival rates were compared between the two groups. [Results] The toxicity in CR group was higher than that in control group（81.1% vs. 67.6%）（P=0.1936）. One-and 3-year survival were 86.5%, 67.6% in CR group, and 64.7%, 41.2% in CR group, respectively, with significantly difference between the two groups （P=-0.0317 for 1-year, P=0.0256 for 3-year）. [Conclusions]Postoperative chemotherapy with TAX＋UFF regimen and concurrent radiotherapy improves the 1-and 3-year survival rates in the patients with advanced gastric carcinoma compared to chemotherapy alone, and the toxicity of chemoradiotherapy is well tolerable.

关 键 词：胃肿瘤 药物疗法 联合 放射疗法 紫杉醇 优福定 氟尿嘧啶 

分 类 号：R735.2[医药卫生—肿瘤]